Cost-effectiveness of blood culture and a multiplex real-time PCR in hematological patients with suspected sepsis: An observational propensity score-matched study

Expert Review of Molecular Diagnostics

Volumn 14, Issue 5, 2014, Pages 623-632

  Mancini, Nicasio ^a   Sambri, Vittorio ^b,c   Corti, Consuelo ^d   Ghidoli, Nadia ^a   Tolomelli, Giulia ^e   Paolucci, Michela ^e   Clerici, Daniela ^d   Carletti, Silvia ^a   Greco, Raffaella ^d   Tassara, Michela ^d   Pizzorno, Beatrice ^f   Zaniolo, Orietta ^g   Povero, Massimiliano ^g   Pradelli, Lorenzo ^g   Burioni, Roberto ^a   Stanzani, Marta ^e   Landini, Maria Paola ^e   Ciceri, Fabio ^d   Clementi, Massimo ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Unit of Clinical Microbiology Greater Romagna Area Hub Laboratory Pievesestina   (Italy)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f Molecular Diagnostics Roche Diagnostics   (Italy)

^g AdRes Health Economics and Outcomes Research   (Italy)

Author keywords

Sepsis

Indexed keywords

AMINOGLYCOSIDE; ANTIFUNGAL AGENT; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; MACROLIDE; QUINOLONE DERIVATIVE;

ANTIBIOTIC THERAPY; ARTICLE; BLOOD CULTURE; BLOOD SAMPLING; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; DISEASE DURATION; DRUG COST; HEALTH CARE COST; HEMATOLOGIC DISEASE; HUMAN; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROPENSITY SCORE; REAL TIME POLYMERASE CHAIN REACTION; SEPSIS; ADULT; AGED; BLOOD; ECONOMICS; EUROPE; EVALUATION STUDY; FEMALE; HEALTH CARE QUALITY; MALE; MIDDLE AGED; MOLECULAR DIAGNOSIS; MULTIPLEX POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; STANDARDS;

ADULT; AGED; COST-BENEFIT ANALYSIS; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; MULTIPLEX POLYMERASE CHAIN REACTION; PROCESS ASSESSMENT (HEALTH CARE); PROPENSITY SCORE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SEPSIS;

EID: 84901266851     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2014.916212     Document Type: Article

References (32)

1. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348(16): 1546-54
2. Ginde AA, Moss M, Shapiro NI, Schwartz RS. Impact of older age and nursing home residence on clinical outcomes of US emergency department visits for severe sepsis. J Crit Care 2013; 28(5):606-11
3. Lagu T, Rothberg MB, Shieh MS, et al. What is the best method for estimating the burden of severe sepsis in the United States?. J Crit Care 2012;27(4):414 e411-419
4. Hall MJ, Williams SN, Defrances CJ, Golosinkiy A. Inpatient care for septicemia or sepsis: A challenge for patients and hospitals. NCHS Data Brief 2011;62:1-8
5. Wang HE, Shapiro NI, Angus DC, Yealy DM. National estimates of severe sepsis in United States emergency departments. Crit Care Med 2007;35(8): 1928-36 (Pubitemid 47220368
6. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: A trend analysis from 1993 to 2003. Crit Care Med 2007;35(5): 1244-50
7. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013;41(2):580-637
8. Uittenbogaard AJ, De Deckere ER, Sandel MH, et al. Impact of the diagnostic process on the accuracy of source identification and time to antibiotics in septic emergency department patients. Eur J Emerg Med 2013. [Epub ahead of print]
9. Conde KA, Silva E, Silva CO, et al. Differences in sepsis treatment and outcomes between public and private hospitals in brazil: A multicenter observational study. PLoS One 2013;8(6): E64790
10. Cornaglia G, Giamarellou H, Rossolini GM. Metallo-beta-lactamases: A last frontier for beta-lactams?. Lancet Infect Dis 2011;11(5): 381-93
11. Burchardi H, Schneider H. Economic aspects of severe sepsis: A review of intensive care unit costs, cost of illness and cost effectiveness of therapy. Pharmacoeconomics 2004;22(12):793-813 (Pubitemid 39158998
12. Moerer O, Plock E, Mgbor U, et al. A German national prevalence study on the cost of intensive care: An evaluation from 51 intensive care units. Crit Care 2007; 11(3):R69
13. Chalupka AN, Talmor D. The economics of sepsis. Crit Care Clin 2012;28(1): 57-76, vi
14. Reinhart K, Bauer M, Riedemann NC, Hartog CS. New approaches to sepsis: Molecular diagnostics and biomarkers. Clin Microbiol Rev 2012;25(4):609-34
15. Mancini N, Carletti S, Ghidoli N, et al. The era of molecular and other non-culture-based methods in diagnosis of sepsis. Clin Microbiol Rev 2010;23(1): 235-51
16. Mancini N, Clerici D, Diotti R, et al. Molecular diagnosis of sepsis in neutropenic patients with haematological malignancies. J Med Microbiol 2008;57(Pt 5):601-4 (Pubitemid 351632907
17. Tissari P, Zumla A, Tarkka E, et al. Accurate and rapid identification of bacterial species from positive blood cultures with a DNA-based microarray platform: An observational study. Lancet 2010; 375(9710):224-30
18. Jordana-Lluch E, Carolan HE, Gimenez M, et al. Rapid diagnosis of bloodstream infections with PCR followed by mass spectrometry. PLoS One 2013;8(4):e62108
19. Paolucci M, Stanzani M, Melchionda F, et al. Routine use of a real-Time polymerase chain reaction method for detection of bloodstream infections in neutropaenic patients. Diagn Microbiol Infect Dis 2013; 75(2):130-4
20. Dark P, Dunn G, Chadwick P, et al. The clinical diagnostic accuracy of rapid detection of healthcare-Associated bloodstream infection in intensive care using multipathogen real-Time PCR technology. BMJ Open 2011;1(1):e000181
21. Mancini N, Poloniato A, Ghidoli N, et al. Potential role of the detection of enterobacterial DNA in blood for the management of neonatal necrotizing enterocolitis. J Med Microbiol 2012; 61(Pt 10):1465-72
22. Mato A, Fuchs BD, Heitjan DF, et al. Utility of the systemic inflammatory response syndrome (SIRS) criteria in predicting the onset of septic shock in hospitalized patients with hematologic malignancies. Cancer Biol Ther 2009;8(12): 1095-100
23. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 2011;10(2):150-61
24. Caselli D, Cesaro S, Ziino O, et al. A prospective, randomized study of empirical antifungal therapy for the treatment of chemotherapy-induced febrile neutropenia in children. Br J Haematol 2012;158(2):249-55
25. Gristina GR, Antonelli M, Conti G, et al. Noninvasive versus invasive ventilation for acute respiratory failure in patients with hematologic malignancies: A 5-year multicenter observational survey. Crit Care Med 2011;39(10):2232-9
26. Mclaughlin AM, Hardt J, Canavan JB, Donnelly MB. Determining the economic cost of ICU treatment: A prospective "micro-costing" study. Intensive Care Med 2009;35(12):2135-40
27. Bates DW, Yu DT, Black E, et al. Resource utilization among patients with sepsis syndrome. Infect Control Hosp Epidemiol 2003;24(1):62-70 (Pubitemid 36083924
28. Lagu T, Rothberg MB, Nathanson BH, et al. The relationship between hospital spending and mortality in patients with sepsis. Arch Intern Med 2011;171(4):292-9
29. Morrissey CO, Chen SC, Sorrell TC, et al. Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: A randomised controlled trial. Lancet Infect Dis 2013;13(6):519-28
30. Vandijck DM, Depaemelaere M, Labeau SO, et al. Daily cost of antimicrobial therapy in patients with Intensive Care Unit-Acquired, laboratory-confirmed bloodstream infection. Int J Antimicrob Agents 2008;31(2):161-5
31. Bloos F, Bayer O, Sachse S, et al. Attributable costs of patients with candidemia and potential implications of polymerase chain reaction-based pathogen detection on antifungal therapy in patients with sepsis. J Crit Care 2013;28(1):2-8
32. Fattore G, Jommi C. The last decade of Italian pharmaceutical policy: Instability or consolidatioñ. Pharmacoeconomics 2008; 26(1):5-15